Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Summary
CHAPTER-VII
SUMMARY
This variation occurs mainly due to the particle size and solid state
characteristics of Isotretinoin. The particle size of the active is mainly controlled
by the API manufacturer during the recrystallization or purification step. The size
reduction of the bigger particles causes serious blow in the purity and its physical
characteristics due to the energy intensive milling process. Hence such process is
mostly discouraged in the formulation industry but the quality of the product is
Design and Development of a Self Nano Emulsifying Drug
Delivery System (SNEDDS) for Isotretinoin with enhanced Oral
Bioavailability and Improved Stability 223
Chapter 7
Summary
built through the input and in-process controls by controlling the API particle size
in a narrow range at the vendor level itself. This makes the condition more
complex and increases the cost of the active material and ultimately adds on the
cost of the final formulation and makes the treatment expensive.
In the present study both, Peppermint oil alone and mixture of Peppermint
oil and Triacetin (1:1) were tested for phase behaviour studies with Polysorbate-
80, Cremophore RH40 and Gelucire 44/14 as surfactants and Transcutol HP as the
Design and Development of a Self Nano Emulsifying Drug
Delivery System (SNEDDS) for Isotretinoin with enhanced Oral
Bioavailability and Improved Stability 225
Chapter 7
Summary
cosurfactant to form S/CoS mixture. Based on solubility data, about 24 mg of
Isotretinoin is soluble in 1 g of Peppermint oil. In order to maximize the drug
loading capacity in minimum quantity of Peppermint oil, it was combined with
Triacetin (1:1) to produce a similar solubility effect with less usage of Peppermint
oil. The nanoemulsion existence area increased as the S/CoS ratio increased.
Thus, an S/CoS ratio between 3:1 and 4:1 was selected for the formulation study.
The selected S/CoS ratio between 3:1 and 4:1 were evaluated for titration after
drug loading. Titration studies revealed that 3:1 S/CoS ratio produced microfine
crystals upon standing. Surfactant is anticipated to enter the water phase and
redistribute mainly between the water phase and the emulsion-water interface,
resulting in a loss of solvent capacity of the vehicle. Thus, the problem of
precipitation was solved by increasing the surfactant proportion (S/CoS [4:1]) in
the system.
As seen from the ternary plot, Peppermint oil alone or in combination with
Triacetin in the ratio of 1:1 with Polysorbate 80 as the surfactant and Transcutol
HP as the cosurfactant gave a wider nanoemulsion region at a S/CoS ratio of 4:1.
Thus, Peppermint oil alone or in combination with Triacetin in the ratio of 1:1
with Polysorbate 80 as the surfactant and Transcutol HP as the cosurfactant was
selected as the preferred vehicle for the optimized formulation. The inclusion of
drug narrowed the nanoemulsion existence area, because inclusion of the drug in
the lipid phase led to expansion of the lipid phase and consequently a need for a
higher S/CoS ratio for stabilization.
Freeze thawing process showed that there was very slight recrystallization
at freezing temperature. So in order to solve this stability issue, solidifying agents
such as PEG 6000 and Poloxamer 407 were added to the SNEDDS formulation to
make a semisolid composition.
It was observed that there was no significant change in the drug release by
adding solidifying agents. However it was observed that PEG 6000 had better
solidifying capacity and faster drug release. Based on the above findings, the final
composition with solidifying agent PEG 6000 was prepared and subjected for
stability studies.
Generally, SNEDD formulations are put into hard gelatin capsules as the
final dosage form. However, liquid-filled hard gelatin capsules are susceptible to
leakage, and the entire system has a very limited shelf life owing to its liquid
characteristics and the possibility of precipitation of the drug from the system.
Thus, the developed formulation with solidifying agent PEG 6000 was subjected
to stability studies to evaluate its stability and integrity of the dosage form. The